ALTERITY THERAPEUTICS LIMITED — Investor Relations & Filings

Alterity Therapeutics Limited is a clinical-stage company focused on developing disease-modifying therapies for neurodegenerative disorders. The company's research and development efforts center on addressing the underlying pathology of conditions such as Multiple System Atrophy (MSA) and Parkinson's disease. Its lead therapeutic candidate, ATH434, is an orally administered small molecule designed to redistribute excess iron in the brain, thereby inhibiting the aggregation of alpha-synuclein and reducing oxidative stress. By targeting these specific mechanisms, the company aims to preserve neuronal integrity and slow the progression of parkinsonian diseases. Alterity utilizes a specialized platform to identify compounds that modulate metal-protein interactions, focusing on first-in-class treatments for orphan diseases with high unmet medical needs.